

ASX Announcement

New Director joins Regeneus Board of Directors

Sydney, Australia – 23 February 2015

Regenerative medicine company, Regeneus Ltd (ASX: RGS) is pleased to announce the appointment of Dr Glen Richards as an independent non-executive director of Regeneus with effect from April.

Dr Richards was the founding Managing Director of Greencross (ASX: GXL) and over 20 years built it into Australia's largest veterinary healthcare group with over 115 veterinary practices and 195 vet specialty stores and led its merger with Petbarn. Dr Richards continues as a non-executive director of Greencross.

Dr Richards said: "I'm pleased to join the Board of Regeneus and look forward to making a contribution to the growth and success of the company. I believe that cell based regenerative medicine will play an important role in the future of veterinary and human healthcare and I look forward to Regeneus playing a leading role in bringing new and useful cell therapies to market".

Regeneus Chairman, Dr Roger Aston said: "On behalf of the Directors, I welcome Glen to the Regeneus Board. Dr Richards has a rare combination of clinical and business experience gained from his leadership role in building Greencross into Australia's leading veterinary healthcare group. His skills, experience and network make him a valuable and strategic addition to the Board particularly as we develop and commercialise our veterinary products for musculoskeletal disease and oncology conditions".

ENDS

About Regeneus:

Regeneus Ltd (ASX: RGS) is an ASX-listed clinical-stage regenerative medicine company developing and commercialising a portfolio of autologous (patient's cells) and allogeneic (donor cells) cell therapies to address unmet medical needs in the human and veterinary health markets with a focus on musculoskeletal disease, oncology conditions and dermatology. Regeneus is in the clinical-stage of development of its allogeneic off-the-shelf adipose stem cell therapies for musculoskeletal disease in animals (**CryoShot**) and humans (**Progenza**). The autologous therapeutic canine cancer vaccine (**Kvax**) is in marketing trials in Australia and the US and the human cancer vaccine is on track for a first in man trial commencing in the first half 2015.

Contact for further information:

Investors:

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au